MX2022012165A - Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. - Google Patents
Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19.Info
- Publication number
- MX2022012165A MX2022012165A MX2022012165A MX2022012165A MX2022012165A MX 2022012165 A MX2022012165 A MX 2022012165A MX 2022012165 A MX2022012165 A MX 2022012165A MX 2022012165 A MX2022012165 A MX 2022012165A MX 2022012165 A MX2022012165 A MX 2022012165A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- sars
- formulations
- proteins
- interaction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021013770 | 2020-03-29 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021054151 | 2020-12-12 | ||
| PCT/IN2021/050325 WO2021199078A2 (en) | 2020-03-29 | 2021-03-30 | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012165A true MX2022012165A (es) | 2023-01-24 |
Family
ID=77927896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012165A MX2022012165A (es) | 2020-03-29 | 2021-03-30 | Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240226120A1 (OSRAM) |
| EP (1) | EP4126913A4 (OSRAM) |
| JP (1) | JP2023528561A (OSRAM) |
| CN (1) | CN115968375A (OSRAM) |
| AU (1) | AU2021247269A1 (OSRAM) |
| BR (1) | BR112022019649A2 (OSRAM) |
| IL (1) | IL296892A (OSRAM) |
| MX (1) | MX2022012165A (OSRAM) |
| WO (1) | WO2021199078A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
| CN115531315B (zh) * | 2022-12-05 | 2023-04-07 | 上海惠盾因泰生物科技有限公司 | 重组人干扰素λ1鼻喷雾剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080043A1 (en) * | 2002-03-18 | 2003-10-02 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
| EP1559423A1 (en) * | 2004-02-02 | 2005-08-03 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Medicinal acidic cannabinoids |
| US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
| NL2009671C2 (en) * | 2012-10-19 | 2014-04-23 | Fytagoras B V | New antiviral use for acidic cannabinoids. |
| US10456435B2 (en) * | 2015-07-15 | 2019-10-29 | Christopher A. MCELVANY | Topical antiviral formulations and methods of using the same |
| WO2020257588A1 (en) * | 2019-06-20 | 2020-12-24 | Shaman Naturals, Llc | Compositions for preventing and treating viral infections |
| CN115916336A (zh) * | 2020-02-19 | 2023-04-04 | 施里玛·麦钱特 | 大麻二酚的组合物和治疗用途 |
| US11338010B2 (en) * | 2020-03-30 | 2022-05-24 | Suzhou Kintor Pharmaceuticals, Inc. | Systems, methods, and kits for diagnostics and treatment of viral respiratory infection |
| EP4149445A1 (en) * | 2020-05-11 | 2023-03-22 | ADD Advanced Drug Delivery Technologies, Ltd. | Uses and formulations of cannabinoids |
| WO2021231810A1 (en) * | 2020-05-14 | 2021-11-18 | Augusta University Research Institute, Inc. | Cannabidiol as a therapeutic modality for covid-19 |
| CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
-
2021
- 2021-03-30 IL IL296892A patent/IL296892A/en unknown
- 2021-03-30 JP JP2022560025A patent/JP2023528561A/ja active Pending
- 2021-03-30 CN CN202180038369.XA patent/CN115968375A/zh active Pending
- 2021-03-30 EP EP21781346.8A patent/EP4126913A4/en not_active Withdrawn
- 2021-03-30 US US17/915,862 patent/US20240226120A1/en not_active Abandoned
- 2021-03-30 AU AU2021247269A patent/AU2021247269A1/en active Pending
- 2021-03-30 WO PCT/IN2021/050325 patent/WO2021199078A2/en not_active Ceased
- 2021-03-30 MX MX2022012165A patent/MX2022012165A/es unknown
- 2021-03-30 BR BR112022019649A patent/BR112022019649A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126913A2 (en) | 2023-02-08 |
| WO2021199078A2 (en) | 2021-10-07 |
| AU2021247269A1 (en) | 2022-12-01 |
| WO2021199078A3 (en) | 2021-12-09 |
| CN115968375A (zh) | 2023-04-14 |
| JP2023528561A (ja) | 2023-07-05 |
| US20240226120A1 (en) | 2024-07-11 |
| IL296892A (en) | 2022-12-01 |
| EP4126913A4 (en) | 2024-09-18 |
| BR112022019649A2 (pt) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021199078A3 (en) | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. | |
| BR112021023340A2 (pt) | Composições compreendendo uma linhagem bacteriana de lactobacillus paracasei e ácido hialurônico e uso do mesmo para o tratamento da pele | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BRPI0415315A (pt) | métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica | |
| BR112021022283A2 (pt) | Novas endolisinas de gardnerella e usos das mesmas | |
| EP4477267A3 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| CN106668832A (zh) | 一种多肽在制备治疗肠道病毒感染药物的应用 | |
| CN106620646A (zh) | 一种多肽在制备用于治疗皮炎湿疹的药物中的用途 | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| BR112015023806A2 (pt) | Novos regimes de dosagem de celgosivir para o tratamento de dengue | |
| JP2010241786A (ja) | ハチ毒を有効成分とする創傷又は火傷治療用組成物 | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| CL2025003377A1 (es) | Tratamiento de afecciones inflamatorias que comprende imu-856. | |
| BR112023024701A2 (pt) | Métodos de tratamento de doenças do fígado | |
| MX2025000682A (es) | Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| MX2021015796A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| WO2020061067A8 (en) | Compositions and methods for treating bone injury | |
| BR112023020732A2 (pt) | Vetor lentiviral para o tratamento da hepatite b, método e preparação de partículas lentivirais para o tratamento da mesma e composição farmacêutica para o tratamento e/ou prevenção da infecção pelo vírus da hepatite b | |
| CR20220453A (es) | Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen | |
| AR122718A1 (es) | Formulaciones | |
| MX2023005663A (es) | Tratamientos respiratorios. |